Colorectal Carcinoma Clinical Trial
Official title:
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
This phase II trial studies how well savolitinib works in treating patients with MET amplified colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVE: I. To estimate the objective response rate (ORR) of savolitinib in patients with MET amplified metastatic colorectal cancer (CRC). SECONDARY OBJECTIVES: I. To describe the clinical activity (duration of response, progression free survival [PFS]) of savolitinib in patients with MET amplified metastatic CRC. II. To describe the toxicities of savolitinib in patients with MET amplified metastatic CRC. III. To explore the effect of RAS mutation status on response to savolitinib. IV. To explore any correlation between tissue and blood based biomarkers and clinical outcomes. OUTLINE: Patients receive savolitinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, and then every 12 weeks thereafter for up to 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04444232 -
Cancer Communication Within Hispanic Social Networks
|
N/A | |
| Recruiting |
NCT06233253 -
Online Mindfulness-Based Intervention to Decrease Pre-Procedural Anxiety Before a First-Time Screening Colonoscopy
|
N/A | |
| Recruiting |
NCT05799820 -
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
|
Phase 2 | |
| Recruiting |
NCT04666727 -
Role of Diet on the Microbiome of the Digestive System
|
||
| Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
| Recruiting |
NCT02376452 -
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
|
Phase 2 | |
| Completed |
NCT02254486 -
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
|
Phase 3 | |
| Completed |
NCT01486251 -
Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
|
N/A | |
| Terminated |
NCT01233544 -
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
|
Phase 3 | |
| Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
| Completed |
NCT00704600 -
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
|
Phase 1/Phase 2 | |
| Completed |
NCT00485316 -
Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma
|
Phase 3 | |
| Recruiting |
NCT04430738 -
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
|
Phase 1/Phase 2 | |
| Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
| Completed |
NCT05022511 -
Three Birds With One Stone
|
N/A | |
| Completed |
NCT04607291 -
Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening
|
Phase 1 | |
| Not yet recruiting |
NCT03969784 -
Microparticles in Peritoneal Carcinomatosis of Colorectal Origin
|
N/A | |
| Not yet recruiting |
NCT05630794 -
Testing ONC201 to Prevent Colorectal Cancer
|
Phase 1 | |
| Terminated |
NCT05291988 -
A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial
|
N/A | |
| Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 |